Keyword: Verzenio (abemaciclib)
With more than 2,000 early retirements settled, Eli Lilly says it's "on track" to hit its goal of cutting 3,500 jobs by year's end.
Lilly's new cancer drug Verzenio faces two tough rivals—Pfizer's Ibrance and Novartis' Kisquali—but the company says it's standing out from the crowd.
Eli Lilly’s Verzenio needs to stand out in a crowd, and now it's less likely that a lung cancer approval could be the solution.
Novartis wants to see some selfies. The company has recruited celebrity firepower for a social media push centered on metastatic breast cancer.
Lilly CEO David Ricks has overhauled his team twice since he took over in January, and this time he's focusing on manufacturing, tech and R&D.
Eli Lilly scored an approval in a next-generation class of breast cancer-fighters that's now dominated by Pfizer's Ibrance.
The breast cancer med Ibrance has been a shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to lift the whole company.
ESMO's research slate included some truly late-breaking data, plus numbers from some closely watched trials. Here's your need-to-know.
Eli Lilly rolled out more positive data for candidate abemaciclib to help it challenge Pfizer's Ibrance and Novartis' Kisqali in breast cancer.
Here comes the second challenger to Pfizer’s fast-growing Ibrance—Lilly's abemaciclib—and potentially sooner than the defender had expected.